Circulating interleukin-8 and plasminogen activator inhibitor-1 are increased in women with ovarian carcinoma

Results in Immunology

Volumn 2, Issue , 2012, Pages 190-195

  Aune, Guro ^a   Stunes, Astrid Kamilla ^a   Lian, Aina Mari ^b   Reseland, Janne Elin ^b   Tingulstad, Solveig ^c   Torp, Sverre H ^c   Syversen, Unni ^a,c  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Hepatocyte growth factor; Interleukin 8; Ovarian cancer; Plasma markers; Plasminogen activator inhibitor 1

Indexed keywords

CA 125 ANTIGEN; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; SCATTER FACTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME;

EID: 84869036962     PISSN: None     EISSN: 22112839     Source Type: Journal    
DOI: 10.1016/j.rinim.2012.10.003     Document Type: Article

References (45)

1. Friedlander ML Prognostic factors in ovarian cancer. Seminars inOncology 1998, 25:305-314.
2. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ 1993, 306:1030-1034.
3. Alper O, De Santis ML, Stromberg K, Hacker NF, Cho-Chung YS, Salomon DS Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. International Journal of Cancer 2000, 88:566-574.
4. Stany MP, Maxwell GL, Rose GS Clinical decision making using ovarian cancer risk assessment. American Journal of Roentgenology (AJR) 2010, 194:337-342.
5. Aune G, Lian AM, Tingulstad S, Torp SH, Forsmo S, Reseland JE, et al. Increased circulating hepatocyte growth factor (HGF):a marker of epithelial ovarian cancer and an indicator of poor prognosis. Gynecologic Oncology 2011.
6. Weidner KM, Sachs M, Birchmeier W The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells. Journal of Cell Biology 1993, 121:145-154.
7. Tanimoto S, Fukumori T, El-Moula G, Shiirevnyamba A, Kinouchi S, Koizumi T, et al. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor. Journal of Medical Investigation 2008, 55:106-111.
8. Tanaka K, Miki C, Wakuda R, Kobayashi M, Tonouchi H, Kusunoki M Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma. Scandinavian Journal of Gastroenterology 2004, 39:754-760.
9. Taniguchi T, Kitamura M, Arai K, Iwasaki Y, Yamamoto Y, Igari A, et al. Increase in the circulating level of hepatocyte growth factor in gastric cancer patients. British Journal of Cancer 1997, 75:673-677.
10. Seidel C, Borset M, Turesson I, Abildgaard N, Sundan A, Waage A Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group. Blood 1998, 91:806-812.
11. Ness RB, Cottreau C Possible role of ovarian epithelial inflammation in ovarian cancer. Journal of the National Cancer Institute 1999, 91:1459-1467.
12. Lambeck AJ, Crijns AP, Leffers N, Sluiter WJ, ten Hoor KA, Braid M, et al. Serum cytokine profiling as a diagnostic and prognostic tool in ovarian cancer: a potential role for interleukin 7. Clinical Cancer Research 2007, 13:2385-2391.
13. Scambia G, Testa U, Panici PB, Martucci R, Foti E, Petrini M, et al. Interleukin-6 serum levels in patients with gynecological tumors. International Journal of Cancer 1994, 57:318-323.
14. Uslu R, Sanli UA, Dikmen Y, Karabulut B, Ozsaran A, Sezgin C, et al. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. International Journal of Gynecological Cancer 2005, 15:240-245.
15. Clendenen TV, Lundin E, Zeleniuch-Jacquotte A, Koenig KL, Berrino F, Lukanova A, et al. Circulating inflammation markers and risk of epithelial ovarian cancer. Cancer Epidemiology, Biomarkersand Prevention 2011, 20:799-810.
16. Sasaroli D, Coukos G, Scholler N Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet?. Biomarkers in Medicine 2009, 3:275-288.
17. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, et al. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiology, Biomarkersand Prevention 2005, 14:981-987.
18. Benedet JL, Bender H, Jones 3rd H, Ngan HY, Pecorelli S FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. International Journal of Gynecologyand Obstetrics 2000, 70:209-262.
19. Tavassoli FA, Devilee P Pathology and Genetics of Tumours of the Breast and Female Genital Organs 2003, International Agency for Research on Cancer. Lyon.
20. White KL, Vierkant RA, Phelan CM, Fridley BL, Anderson S, Knutson KL, et al. Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer. BMC Cancer 2009, 9:170.
21. Van Waes C, Yu M, Nottingham L, Karin M Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clinical Cancer Research 2007, 13:4956-4959.
22. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, et al. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. Journal of Cancer Research and Clinical Oncology 2010, 136:1079-1088.
23. Nolen B, Marrangoni A, Velikokhatnaya L, Prosser D, Winans M, Gorelik E, et al. A serum based analysis of ovarian epithelial tumorigenesis. Gynecologic Oncology 2009, 112:47-54.
24. Tsai-Turton M, Santillan A, Lu D, Bristow RE, Chan KC, Shih Ie M, et al. p53 autoantibodies, cytokine levels and ovarian carcinogenesis. Gynecologic Oncology 2009, 114:12-17.
25. Lokshin AE, Winans M, Landsittel D, Marrangoni AM, Velikokhatnaya L, Modugno F, et al. Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecologic Oncology 2006, 102:244-251.
26. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. Journal of theNational Cancer Institute 2008, 100:359-372.
27. Brown M, Cohen J, Arun P, Chen Z, Van Waes C NF-kappaB in carcinoma therapy and prevention. Expert Opinion on Therapeutic Targets 2008, 12:1109-1122.
28. Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, et al. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 2005, 24:1749-1766.
29. Muller M, Morotti A, Ponzetto C Activation of NF-kappaB is essential for hepatocyte growth factor-mediated proliferation and tubulogenesis. Molecular and Cellular Biology 2002, 22:1060-1072.
30. Giannopoulou M, Dai C, Tan X, Wen X, Michalopoulos GK, Liu Y Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-kappaB signaling. American Journal of Pathology 2008, 173:30-41.
31. Ito W, Takeda M, Tanabe M, Kihara J, Kato H, Chiba T, et al. Anti-allergic inflammatory effects of hepatocyte growth factor. International Archives of Allergy and Immunology 2008, 146(Suppl. 1):82-87.
32. Grygas J, Steiger N, LeSeur CL, Unger BL, McGee DW Hepatocyte growth factor enhances IL-1beta stimulated IL-8 secretion by Caco-2 epithelial cells. In Vitro Cellularand Developmental Biology-Animal 2007, 43:147-152.
33. Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine 2011, 365:2484-2496.
34. Serin IS, Tanriverdi F, Yilmaz MO, Ozcelik B, Unluhizarci K Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women. Gynecological Endocrinology 2008, 24:117-121.
35. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clinical Cancer Research 2008, 14:1065-1072.
36. Vrzalova J, Prazakova M, Novotny Z, Topolcan O, Casova M, Holubec Jr L Test of ovarian cancer multiplex xMAP technology panel. Anticancer Research 2009, 29:573-576.
37. Kuhn W, Schmalfeldt B, Reuning U, Pache L, Berger U, Ulm K, et al. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc. British Journal of Cancer 1999, 79:1746-1751.
38. Abendstein B, Daxenbichler G, Windbichler G, Zeimet AG, Geurts A, Sweep F, et al. Predictive value of uPA, PAI-1, HER-2 and VEGF in the serum of ovarian cancer patients. Anticancer Research 2000, 20:569-572.
39. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecologic Oncology 2008, 110:374-382.
40. Chen DC, Chung YF, Yeh YT, Chaung HC, Kuo FC, Fu OY, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Letters 2006, 237:109-114.
41. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H Plasma adiponectin and gastric cancer. Clinical Cancer Research 2005, 11:466-472.
42. Petridou ET, Mitsiades N, Gialamas S, Angelopoulos M, Skalkidou A, Dessypris N, et al. Circulating adiponectin levels and expression of adiponectin receptors in relation to lung cancer: two case-control studies. Oncology 2007, 73:261-269.
43. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. European Journal of Cancer 2009, 45:931-991.
44. Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, et al. Ovarian cancer. Critical Reviews in Oncology 2006, 60:159-179.
45. Cancer Registry of Norway. Cancer in Norway 2008-cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer registry of Norway; 2009.